What policies are needed in order to foster breakthrough technologies out of which companies can create innovation successes?
In a fascinating new book – Science, the State and the City – Geoffrey Owen and Michael Hopkins take stock of the UK and European biotech sector and ask why it did not deliver on its promise. It covers a broad range of issues – the scientific development, industrial policy and the general financial conditions for innovation – and raises questions about the quality of innovation and entrepreneurship policy in Europe, especially in light of the climate for innovation in the United States. Why did Europe become a laggard in biotech – and what do the explanations behind it say about general innovation policy in Europe?
Sir Geoffrey Owen, business historian, former Editor of the Financial Times, and Senior Fellow at the London School Economics
Michael Hopkins, Senior Lecturer and Director of Research for the Science Policy Research Unit at the University of Sussex
Eliana Garcés Tolón is the deputy Chief Economist at the European Commission’s DG Internal Market, Industry, Entrepreneurship and SMEs
Björn Weigel is a business investor and entrepreneur, and co-author of the forthcoming book, The Innovation Illusion